25rhk168 10.3205/25rhk168 urn:nbn:de:0183-25rhk1689 Meeting Abstract Hueber Hueber Axel A

Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University, Nürnberg

author Werner Werner Stephanie Gabriele SG

RHIO Research Institute, Düsseldorf

author Schwarze Schwarze Ilka I

Practice of Internal Rheumatology, Leipzig

author Baraliakos Baraliakos Xenofon X

Rheumazentrum Ruhrgebiet, Herne

author Fiene Fiene Michael M

Rheumazentrum Greifswald, Greifswald

author Walter Walter Jochen J

Practice of Rheumatology and Osteology, Rendsburg

author Bessette Bessette Louis L

Department of Medicine, Laval University, Quebec

author Allard-Chamard Allard-Chamard Hugues H

Division of Rheumatology, Faculty of Medicine and Health Sciences, University of Sherbrooke, Quebec

author Laliberte Laliberte Marie- Claude MC

AbbVie Canada, Quebec

author Girard Girard Tanya T

AbbVie Canada, Quebec

author Jeromin Jeromin Katharina K

AbbVie Germany, Wiesbaden

author Baschuk Baschuk Nikola N

AbbVie Germany, Wiesbaden

author German Medical Science GMS Publishing House

Düsseldorf

610 20250917 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0627 168 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie 53. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 39. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2025 Spondyloarthritiden Wiesbaden 20250917 20250920 SpA.31 TextIntroduction: Upadacitinib (UPA) is an oral, reversible JAK inhibitor approved for the treatment of active PsA. Oligoarticular PsA (oPsA) typically affects ≤4 peripheral joints and can progress to polyarticular PsA (pPsA), potentially causing more joint damage . This analysis aims to assess if the achievement of minimal disease activity (MDA) during UPA treatment impacts oPsA and pPsA patients-reported outcomes (PROs).Methods: UPJOINT (NCT04758117) is a multicenter, prospective, open-label, observational study being conducted in Germany and Canada in adults (≥18 years) with PsA involving at least one swollen joint (SJC ≥1) of 66; ≥35% of the study population have oPsA. Patients of both subgroups were stratified into MDA achievers and non- achievers after 24 weeks of UPA treatment and analyzed accordingly for PROs like, pain, SF-12, DLQi and HAQ-DI (as HAQ-DI and pain is a component of MDA and no independent measure it is only shown to provide all recorded PROs).Results: This posthoc analysis of the UpJoint study included 370 PsA patients with baseline data. Of which 38,7% were diagnosed with oPSA. A proportion of 55,8% oPSA and 32% pPsA patients achieved MDA at week 24.Patients with MDA at week 24 in both PsA subgroups showed significant improvement from baseline in pain and health related quality of life scores, measured by SF-12 physical, SF-12 mental, HAQ-DI and DLQi, compared to patients that did not achieve MDA.Importantly, regardless if belonging to the oPsA or pPsA subgroups, patients with MDA reported comparable scores in all measured PROs at week 24. For both patient groups the reported PRO scores were significantly improved in MDA achievers compared to the respective patient group that did not achieve MDA at week 24.Conclusion: Regardless of the PsA subgroup of oPsA or pPsA, PRO scores were comparable within MDA achievers, highlighting the impact and value of MDA for patients’ wellbeing and quality of life. Marchesoni A Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype 2018 Rheumatol Ther 311-6 Marchesoni A. Oligoarticular Psoriatic Arthritis: Addressing Clinical Challenges in an Intriguing Phenotype. Rheumatol Ther. 2018 Dec;5(2):311-6. DOI: 10.1007/s40744-018-0115-5 http://dx.doi.org/10.1007/s40744-018-0115-5 0 0 0 0